Fortress Biotech, Inc. (FBIO)
| Market Cap | 44.63M |
| Revenue (ttm) | 80.97M |
| Net Income (ttm) | -82.32M |
| Shares Out | 14.83M |
| EPS (ttm) | 4.31 |
| PE Ratio | 0.70 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,184,451 |
| Open | 3.24 |
| Previous Close | 3.89 |
| Day's Range | 2.94 - 3.34 |
| 52-Week Range | 1.24 - 17.40 |
| Beta | 2.01 |
| Analysts | Strong Buy |
| Price Target | 55.00 (+1,727.24%) |
| Earnings Date | Nov 14, 2023 |
About FBIO
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It a... [Read more]
Financial Performance
In 2022, FBIO's revenue was $75.74 million, an increase of 10.11% compared to the previous year's $68.79 million. Losses were -$86.58 million, 33.8% more than in 2021.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price forecast is $55.0, which is an increase of 1,727.24% from the latest price.
News
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MIAMI, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and comme...
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.
Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales milestones
Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics
Sentynl receives worldwide proprietary rights and U.S. FDA documents pertaining to CUTX-101 copper histidinate CUTX-101 has potential to be the first FDA-approved treatment for Menkes disease; rolling...
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
On track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023 On track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023
Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Total consolidated net revenue was $34.8 million in the third quarter of 2023, a 100% increase from total consolidated net revenue of $17.4 million in the second quarter of 2023
Fortress Biotech Announces Closing of $10.0 Million Public Offering
MIAMI, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and comme...
Fortress Biotech Announces Pricing of $10.0 Million Public Offering
MIAMI, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and comme...
Fortress Biotech Announces Launch of Proposed Public Offering
MIAMI, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and comme...
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Company generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023
Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023
Company to host conference call to discuss financial results and provide a corporate update on November 7, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide...
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)
Study demonstrated systemic exposure of DFD-29 was significantly lower than that of Solodyn (105 mg) Data presented at 43rd Annual Fall Clinical Dermatology Conference New Drug Application submission ...
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1
Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for whic...
Fortress Biotech Announces Reverse Stock Split
MIAMI, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and c...
Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference
Fortress Biotech will present at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City on Thursday, October 12, 2023, at 11:00 a.m. ET.
Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing o...
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations
SCOTTSDALE, Ariz., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses ...
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
The Company generated total net revenues of $17.2 million in the second quarter of 2023, a 41% increase from $12.2 million in the first quarter of 2023
Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023
MIAMI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or...
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023
Company to host conference call to discuss financial results and provide a corporate update on August 8, 2023 at 4:30 p.m. ET
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023
Company to host conference call to discuss financial results and provide a corporate update the week of August 7, 2023 Company to host conference call to discuss financial results and provide a corpor...
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults
The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues
Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023
SCOTTSDALE, Ariz., July 03, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and...
Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States
Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic and safety profile between U.S. and Japanese healthy subjects
Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program
Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk o...